{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Phase II: Assess if PRGN-2009 results in significantly prolonged survival at three years as compared to the expected 80% three-year historical survival in p16-positive oropharyngeal cancer (OPC) participants. Three-year overall survival will be measured using a Kaplan-Meier curve and will be compared descriptively with the historical benchmark. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.","groups":[{"description":"Phase II in newly diagnosed, untreated, locoregional p16-positove oropharyngeal cancer (OPC) (cohort 2) and in newly diagnosed. Arm 2A: HPV vaccine at recommended phase 2 dose (RP2D) as determined at completion of Arm 1A. HPV vaccine at 5x10\\^11 Viral Particles (VP).","id":"OG000","title":"Phase II Cohort 2, Arm 2A, Dose Level 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Phase II: Overall Survival at 3 Years Compared With Historical Cohort","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}